Novo Nordisk adds four registrations: new molecule trial, CagriSema switch study, real-world dataSep 30Weekly roundup, 7 itemsCagrisemaNNC0705-0002Updated
Novo Nordisk registers Phase 3 zenagamtide trial in T2D and first-in-human study for NNC0705-0002Sep 1Weekly roundup, 2 itemsNNC0705-0002Novo Nordisk A/S
Sign inSign in